Demo Sign up Log In

Novo Nordisk A/S Common Stock (NVO)

R&D Expenses

kr 58.11B

TTM · Period ending: Jun 30, 2026 · DKK

NVO R&D Expenses

Latest reportedkr 58.11B DKKperiod endingJun 30, 2026

Latest reportedkr 58.11B DKKperiod endingJun 30, 2026

NVO R&D Expenses · DKK (kr 0.00 → kr 58.11B)

Annual R&D Expenses

High-resolution chart · PNG

NVO r&d expenses history

Annual fiscal periods · DKK. Dates are reporting period ends; fiscal years can differ from calendar years.

Novo Nordisk A/S Common Stock R&D Expenses — Annual fiscal periods (DKK)
Period ending	R&D Expenses (DKK)
Dec 31, 2025	52,039,000,000
Dec 31, 2024	48,062,000,000
Dec 31, 2023	32,443,000,000
Dec 31, 2022	24,047,000,000
Dec 31, 2021	17,772,000,000
Dec 31, 2020	15,462,000,000
Dec 31, 2019	14,220,000,000
Dec 31, 2018	14,805,000,000
Dec 31, 2017	14,014,000,000
Dec 31, 2016	14,563,000,000
Dec 31, 2015	13,608,000,000
Dec 31, 2014	13,762,000,000
Dec 31, 2013	11,733,000,000
Dec 31, 2012	10,897,000,000
Dec 31, 2011	9,628,000,000
Dec 31, 2010	9,602,000,000
Dec 31, 2009	7,864,000,000
Dec 31, 2008	7,874,022,000
Dec 31, 2007	8,550,608,000
Dec 31, 2006	6,317,371,000
Dec 31, 2005	5,074,704,000
Dec 31, 2004	4,384,760,000
Dec 31, 2003	4,203,930,000
Dec 31, 2002	4,133,371,000
Dec 31, 2001	3,959,801,000
Dec 31, 2000	3,224,522,000
Dec 31, 1999	2,587,554,000
Dec 31, 1998	2,649,512,000
Dec 31, 1997	2,769,620,000
Dec 31, 1996	0
Dec 31, 1995	0
Dec 31, 1994	0
Dec 31, 1993	0
Dec 31, 1992	0
Dec 31, 1991	0
Dec 31, 1990	0
Dec 31, 1989	0
Dec 31, 1988	0
Dec 31, 1987	0
Dec 31, 1986	0
Dec 31, 1985	0

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.